Byetta Lawsuits Mount, as Federal Product Liability Claims Involving Incretin Mimetics Diabetes Drug

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) May 17, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving a class of diabetes drugs called incretin mimetics continue to mount in a federal multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to an updated Docket Report issued by the U.S. Jud
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations